BioSig Technologies Announces the Appointment of Jerome B. Zeldis to Its Board of Directors

LOS ANGELES, CA--(Marketwired - Apr 9, 2015) - BioSig Technologies (OTCQB: BSGM), today announced that Dr. Jerome B. Zeldis has joined the Company's Board of Directors, effective immediately. Dr. Zeldis has agreed to chair the Nominating Committee at the next regularly scheduled Board meeting.

Jerome Zeldis, MD, PhD brings extensive life sciences experience gained through his career at Celgene, Inc. He is currently Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation, a publicly traded, fully integrated biopharmaceutical company, where he has been employed since 1997. Prior to working at Celgene, Dr. Zeldis worked at Sandoz Research Institute and the Janssen Research Institute in both clinical research and medical development. He has been a board member of several biotechnology companies. He attended Brown University for an AB, MS, followed by Yale University for an M Phil, MD, PhD in Molecular Biophysics and Biochemistry. Dr. Zeldis trained in Internal Medicine at the UCLA Center for the Health Sciences and in Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. He was Assistant Professor of Medicine at the Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School and Professor of Clinical Medicine at the Robert Wood Johnson Medical School in New Brunswick, New Jersey.

Kenneth L Londoner, Executive Chairman and co-Founder of BioSig, stated, "The Board could not be more pleased to welcome Jerry. Dr. Zeldis was an early believer and investor in our science. He has made several visits to our LA office to monitor our progress and evolution of the PURE EP™ platform, including a full day of diligence at the UCLA Cardiac Arrhythmia Center hosted by Dr. Kalyanam Shivkumar, Director and Chief. His contributions to BioSig will be appreciated by all of our shareholders."

Dr. Jerome B. Zeldis said, "I am very pleased with the progress that has been made to improve the detection of arrhythmogenic foci that are the cause of most cases of atrial fibrillation. This will result in better patient outcomes in the treatment of this common disease. I look forward to contributing to this effort as a Board member. "

About BioSig Technologies
BioSig Technologies is a medical device company that has developed a proprietary technology platform designed to greatly improve the $3 billion electrophysiology (EP) marketplace(1) ( Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP System.

PURE EP System is a next-generation surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing guidance in identifying ablation targets - areas of tissue to destroy that otherwise create a heart rhythm disturbance (arrhythmia).

Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019(1) -- making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).

BioSig intends to seek FDA 510(k) approval for the PURE EP System. The Company has already achieved proof of concept validation through UCLA EP & Animal Labs, and is collaborating with several of the nation's most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UCLA Cardiac Arrhythmia Center, and Mayo Clinic.

(1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

(2) HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; *AF includes left atrial tachycardia, left WPW, left atrial flutter.
Investor Relations:
Brian McLaughlin
BioSig Technologies, Inc.
[email protected]

Lora Mikolaitis
BioSig Technologies, Inc.
[email protected]

Suggested Articles

In this week's EuroBiotech Report, Sitryx inks Lilly deal, Genfit downplays COVID-19 impact on NASH data and Gilead tests remdesivir in U.K.

Amgen and new partner Adaptive Biotechnologies are the latest pharma-biotech duo joining forces against the pandemic.

In our EuroBiotech roundup this week, AM-Pharma raises €23 million, Nordic Nanovector makes cuts and Neurimmune, Ethris plan COVID-19 trial.